Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Shares of Amgen Inc. AMGN advanced 1.24% to $297.93 Thursday, on what proved to be an all-around dismal trading session for ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best drug stocks to buy now.

Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles Soria, senior vice president of oncology within global ...

Piper Sandler raised the firm’s price target on Amgen (AMGN) to $329 from $310 and keeps an Overweight rating on the shares. The firm notes the ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to ...

An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its ...